2016 11-17 investor presentation november-2016

1
SEMPERIT GROUP
INVESTOR PRESENTATION
November 2016

Semperit at a glance
Investor Presentation November 2016 I Investor Relations2
Solid balance-
sheet structure
39%
equity ratio
EUR 915
million revenue
EUR 67
million EBIT
Leading market position
with strong brands in the Industrial
and Medical Sectors for more than
190 years
Balanced portfolio
Semperflex Sempertrans Semperform Sempermed
7,053 employees
Worldwide presence
Distribution in more
than 100 countries
22 production sites
worldwide
Note: values stated are for FY 2015

Investment Rationale (p. 4)
Outlook (p. 21)
Appendix (p. 24)
Agenda
3
Operational Development and Financial Performance (p. 11)
Investor Presentation November 2016 I Investor Relations

Investment Rationale
5 reasons to invest in Semperit
1. Strong position in megatrend-driven markets
2. Profitable growth based on a balanced portfolio
3. Long standing application and process engineering tradition,
proven M&A track record
4. High earnings capacity and strong balance sheet
5. Market leading brands, customer focused approach and
globally diversified sales network
4 Investor Presentation November 2016 I Investor Relations

1. Strong position in megatrend-driven markets
Worldwide energy demand
Population growth
Worldwide urbanisation
Global megatrends
+33% to 9.6 billion by 2050
66% urban population
by 2050 (2014: 54%)
+30% by 2035
Medical Sector: Growth market Healthcare
 Rising prosperity and
improving hygienic
standards in emerging
markets
 Increasing life
expectancy and shift in
the age pyramid in
mature markets
 Ø global growth of
glove market
5-6% p.a.
Use of examination gloves
per capita per year
60 - 70
25 - 3010 - 20
Asia South America Europe USA
Source: Semperit
150 - 160
Sempermed
Examination gloves
Globally leading position
Surgical gloves
Leading position in Europe
5
Market impact & growth drivers Products & market position
Industrial Sector:
industrialisation & investments in infrastructure
 On-going industrialisa-
tion and infrastructure
investments
 Expansion of mining
industry
 Growing construction
business
 Rising demand for
Semperflex,
Sempertrans and
Semperform
products
Global construction market
until 2030 (in USD trillion)
Source: Global Construction 2030
8.4
15.5
2015 2030
+85%
Semperflex
Sempertrans
Semperform
Hydraulic hoses
# 3 globally,
leader in hose only
Industrial hoses
# 2-3 in Europe
Conveyor belts
Top Tier / one of the
worldwide leading suppliers
Handrails: leading position
Window profiles:
European player
Cable car rings and
ski foils: leading position

2. Profitable growth based on a balanced portfolio
Ambitious growth strategy …
 True global player through expansion in growth markets
 Capacity expansions and selected acquisitions
 Customer proximity, market orientation and innovation strength
 High performance organisation
Growth targets
 Double digit volume growth 2015-2020 (CAGR)
… based on stability through diversification
 Stable, largely non-cyclical growth
 Expansion of leading global position
 Strengthen market position in medical
and industrial/consumer goods areas
Medical
Sector
 Managing industrial cycles and
on-going high profitability
 Leading position in selected niches
 Grow and maintain market positions
Industrial
Sector
Revenue: Accelerated growth since 2010
in EUR m
463 477 515
574 608 655
588
689
820 829
906 858
915
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014* 2015
CAGR
+4.0%
Revenue growth and high earnings
in %
Source: World Bank, Semperit
Group EBITDA
margin
Industrial Sector:
Revenue Growth in%
Medical Sector:
Revenue Growth in%
GDP Growth
World in %
CAGR
+5.8%
16.3% 13.4% 13.1% 14.6% 11.9%
* restated
6
4.0 2.8 3.1 2.4 3.3
16.6 17.4
3.2
13.4
-12.4
17.8 20.2
-0.8
5.9
1.3
9.1
2010 2011 2012 2013
2014*
10.5%
2015
3.13.4

3. Long standing application and process engineering tradition,
proven M&A track record
High performance organisation for accelerated growth
 Long-standing engineering know-how dates back to 1824
 Strong track record in high-quality production and innovative products
 Growth-orientated organisation to manage organic growth and acquisitions
Latexx Partners acquisition in 2012
 Takeover of Malaysian gloves producer in 2012,
#6 in the world
 Revenue 2011: EUR 104m
 Employees 2011: >2,000
 Expansion of the site in Kamunting with a new glove factory
 Investment volume: EUR 50m
 Production capacity: Doubling to about 12 billion units of
gloves per year (from 6 billion units)
Leeser acquisition in 2015
 Takeover of leading German manufacturer of high-quality
rubber seals in 2015
 Revenue 2014: EUR 37m
 Employees 2014: >200
 Acquisition strengthens market position and had an
immediate positive effect on earnings situation of Semperform
 Integration is proceeding successfully, first synergies
already achieved

4. High earnings capacity and strong balance sheet
Sophisticated Financial Engineering
 Focused financing policy
 Active cost and raw materials management
 Cost awareness and rigid cost controlling on all levels
 Optimised capital structure
 Adaptation of pay-out ratio to about 50% of earnings after tax
(provided the performance and development of the company
permit it)
Strong cash generation and attractive dividend policy
Strong balance sheet and high cash position
Equity Ratio
in %
Cash and cash equivalents
in EUR m
29.4
106.7
137.2
71.5
59.8
2011 2012 2013 2014 2015
Operating Cash flow
in EUR m
Dividend per share
in EUR
1) 0.90 basic dividend + 0.30 anniversary bonus
2) 1.10 basic dividend + 4.90 one-time special
0.8 0.8 1.2
6.0
1.2
2011 2012 2013 2014 2015
61.5
49.3 48.3
53.7
38.7
2011 2012 2013 2014 2015
97.9
133.3
182.6
115.6
126.4
2011 2012 2013 2014 2015
1)
2)

5. Market leading brands, customer focused approach and
globally diversified sales network
Products
• Leading Sempermed brands with
broad product portfolio
• OEM production for customers worldwide
Distribution
• Multi-channel distribution capabilities with
sales offices in Europe, North & South America
and Asia
Products
• Diversified product range in attractive niches
• From basic to premium products to
tailor-made / project business
Distribution
• Focus on high reputation customers
• Strong partners in wholesale
Medical Sector: Revenue by region
Europe
55%
Asia, Africa, other
10%
North & South America
35%
FY 2015 in %
Industrial Sector: Revenue by region
Europe
74%
Asia, Africa, other
15%
North & South America
11%
FY 2015 in %

Outlook (p. 21)
Appendix (p. 24)
Agenda
10

Solid development despite weak market situation
 Solid development through satisfying capacity utilisation and
sales activities
 Industrial sector with volume growth and further gains in
market share despite very difficult markets
 Medical Sector: Focus on core markets as a consequence
of challenging price and cost situation as well as ongoing
Thailand JV dispute
 Predicted drop in revenue and operational earnings
 Revenue decreases by -6.4% to EUR 647.6 million
 EBITDA -4.2% and EBIT -13.5%1)
 Net profit negatively affected by higher financial and tax
expenses
Sound Industrial Sector limits
negative effects of weak Medical Sector
Revenue by segment Q1-3 2016 (vs. Q1-3 20151))
Sempermed
40% (43%)
Semperform
19% (17%)
Sempertrans
17% (18%)
Semperflex
24% (22%)
Europe
69% (65%)
Asia, Africa, others
12% (13%)
North and South America 19% (22%)
Revenue by region Q1-3 2016 (vs. Q1-3 2015)
1) Values for 2015 restated

 Still small volume growth despite economic
headwind and continued mining downturn
 Margins under pressure due to subdued
market demand and price competition
 Satisfactory utilisation of all production
sites
 Volume growth and increase of market
share in all Business Units
 Hydraulic hoses: Good utilisation in
challenging market environment
 Industrial hoses: New capacities highly
utilised due to strong sales performance
Semperflex: Strong performance
Sempertrans: Competing successfully in very challenging markets
Q1-3 2016 vs. Q1-3 20151)
SemperflexSempertrans
-10%Market
EBIT
EBITDA
Revenue
-15%Market
EBIT
EBITDA
Revenue
-1.7%
-2.3%
-4.4%
-6.1%
-12.9%
-18.1%

 Market share gains in decreasing markets
 Profiles: successful market entry in USA;
market share gains in Western and Central
Europe compensated decline in Russia;
 Handrails: business benefits from strong
After-Sales-Market
Semperform: Stable development
Sempermed: Focus on core markets
Semperform
-2%Market
EBIT
EBITDA
Revenue
2) EBITDA and EBIT in 2015 was positively influenced by one-time bad will effect from acquisition of Leeser (EUR 3.2m).
+3.4%
-4.1%
-14.5%
13
Q1-3 2016 vs. Q1-3 20151)
2)
 Global glove market still growing but all
producers affected by margin squeeze
 Thailand JV and start-up costs in Malaysia
put pressure on earnings
 Focus on core markets Europe and
North America
 Cost reduction programme and efficiency
improvements continued
Sempermed
+5%
n.a.
-49,6%
-12.9%
Market
EBIT
EBITDA
Revenue
-78.1%
2)

Q1-3 2016: Slight drop in revenue, stable margins
2) Attributable to the shareholders of Semperit AG Holding
in EUR m
Q1-3 2016
Q1-3 20151)
(restated)
%
Revenue 647.6 692.1 -6.4%
EBITDA 72.2 75.4 -4.2%
EBIT 46.7 53.9 -13.5%
Earnings after tax 23.4 40.1 -41.6%
Profitability
EBITDA margin 11.1% 10.9% +0.2 PP
EBIT margin 7.2% 7.8% -0.6 PP
Earnings per share in EUR2) 1.14 1.95 -41.6%
Key Financials Semperit Group1)

Development of revenue and EBIT per quarter
17.7
21.0
12.8
15.2
Q4
Q3
Q2
Q1 18.6
17.6
66.7
20151)
10.4
2016
46.7
7.0%
9.0%
7.3%
= EBIT margin
15
20151)
Q1 219.5
647.6
2016
Q4
Q3
219.2
208.9
914.7
217.5
233.4
241.3
222.6
5.8%
Revenue per quarter
in EUR m
EBIT per quarter
in EUR m
8.5%
8.0%
5.0%
Q2

Challenging market conditions in all sectors
-38.4
647.6
SempermedSemperform
4.0
Sempertrans
-7.4
Semperflex
-2.7
Q1-Q3 2015
-6.4%
692.1-6.2m
Industrial Sector
Q1-Q3 2016
Revenue by segment Q1-3 2016 vs. Q1-3 2015
in EUR m
-12.9%
Industrial Sector Medical Sector
-1.7% -6.1% +3.4%
-1.6%
= % change

Strong EBIT margins in Industrial Sector
53.9
-6.6m
Industrial Sector
Q1-Q3 2016
46.7
Corporate
Center
10.5
Sempermed
-11.2
Semperform
-2.6
-1.4
Q1-Q3
20151)
Semperflex Sempertrans
-2.6
-13.5%
EBIT by segment Q1-3 2016 vs. Q1-3 20151)
in EUR m
7.2%7.8%
= EBIT margin
-0.3%19.9% 10.2% 12.4%
14.7%

CAPEX and Working Capital Overview
= Trade Working Capital
in % of LTM revenues
-14.0%
Other
Sempermed
Semperform
Sempertrans
Semperflex
Q1-Q3 2016
44.3
4.4
18.5
8.2
3.3
9.9
Q1-Q3 2015
51.5
4.7
23.8
5.4
6.4
11.2
CAPEX per Segment
in EUR m
Components of Working Capital
in EUR m
31 Dec 2015
160.6
-100.7
125.5
135.7
Trade receivables
Trade payables
+3.0%
Inventories
30 Sept 2016
165.3
-94.0
126.0
133.3
17.6% 19.1%

 141m EUR issued in 3 currencies:
US-Dollar / Polish Zloty / Czech Crown
 Maturities of 3, 5 and 7 years
 Currencies for important procurement, production and
sales markets
 Funds are used, among other things, to re-finance existing
financial liabilities and to ensure further expansion of
production sites
 Subscribed by European and Asian investors
 Original placement volume was increased significantly
 Pricing was at the lower end
 Interest rate of slightly above 2% on average for Corporate
Schuldschein loans issued in November 2016
 Total average interest rate for Semperit Group going
forward is about 2%
 Net debt / EBITDA of 2.32x as of 30 September 2016
Corporate Schuldschein Loans issued in November 2016
19
Favourable capital markets used to
diversify financing structureCurrency Split
Czech Crown
14%
Polish Zloty
23%
US-Dollar
63%
Maturity split
5 and 7 years
67%
3 years
33%

Outlook (p. 21)
Appendix (p. 24)
Agenda
20

Outlook 2016: Challenging market conditions weigh on
operational development
 Continued moderate
economic recovery
expected in the
industrialised countries
 Heterogeneous picture in
emerging and developing
countries
 No signs of stimulation of
industry and investments
in China, Russia and
Eastern Europe
Moderate recovery of the
global economy in 2016
 Operational results expected to be below prior year:
EBITDA about -10%, EBIT about -20%
 Risk factors: uncertain outlook for commodity prices and currency risks
Industrial Sector
 Semperflex: Relatively stable, better than market,
strong market position and strategic partnerships mitigate cyclicality
 Sempertrans: Cyclical decreasing demand,
price pressure intensified, development in accordance with market
 Semperform: Relatively stable,
market share gains in decreasing markets,
globalisation of profile business
Medical Sector
 Focus on core markets Europe and North America
 Efficiency, optimisation and cost cutting
measures under way
 Commissioning of the new production
capacities in Malaysia
 Negative impact from joint venture in Thailand
likely to continue
Markets put pressure on operational development
Growth targets
 Average double-digit
volume growth 2015-
2020 (CAGR)

Contact and financial calendar
22
Financial Calendar 2017
23/3/2017 Publication of 2016 annual financial
statements and press conference
26/4/2017 Annual General Meeting
2/5/2017 Ex-dividend day
4/5/2017 Dividend payment day
16/5/2017 Report on Q1 2017
17/8/2017 Report on H1 2017
16/11/2017 Report on Q1-3 2017
Investor Relations Semperit Group
Stefan Marin, Head of Investor Relations
investor@semperitgroup.com
+43 1 79777 - 210
www.semperitgroup.com/en/ir
Modecenterstrasse 22
1031 Vienna, Austria
Disclaimer
The information provided in this presentation does not constitute an offer for the sale of securities nor an invitation to submit
an offer to purchase shares of Semperit AG Holding, but exclusively serves information purposes. Rounding of differences in
the totalling of rounded amounts and percentages may arise from the automatic processing of data.
The forecasts, plans and forward-looking statements contained in this presentation are based on the knowledge and
information available and the assessments made at the time that this report was prepared. As is true of all forward-looking
statements, these statements are subject to risk and uncertainties. As a result, the actual events may deviate significantly
from these expectations. No liability whatsoever is assumed for the accuracy of projections or for the achievement of planned
targets or for any other forward-looking statements.

Outlook (p. 21)
Appendix (p. 24)
Agenda
23

Composition of Financial Results
24
Financial result Q1-3 2015
in EUR m
-5.0
-4.6
-4.2
-22.2
26.0
Financial
income incl.
FX gains and
interest income
12.2
Interest expenses
-12.7
-4.7
Profit/loss attribu-
table to redeem-
able non-con-
trolling interests
-5.5
Financial
expenses incl.
FX losses and
other expenses
-14.7
Financial
result
Financial result Q1-3 2016
in EUR m
 Q1-3 2015: Financial result
primarily influenced by FX gains
 Q1-3 2016: Negative impact of
FX losses (mainly in Q1 2016)
and higher borrowing costs on
financial result
Development of financial result

In EUR m
Revenue
EBITDA
EBITDA margin
EBIT
EBIT margin
Earnings after tax
Earnings per share in EUR3)
Investments
Employees
(at reporting date)
Group and Sectors: Q1-3 2016 vs. Q1-3 2015
Q1-3 2016
Q1-3 2015
restated2) %
389.3 395.5 -1.6%
71.7 75.6 -5.1%
18.4% 19.1% -0.7 PP
57.1 63.7 -10.3%
14.7% 16.1% -1.4 PP
21.3 23.0 -7.4%
3,576 3,583 -0.2%
Q1-3 2016
Q1-3 2015
restated2)
%
258.3 296.7 -12.9%
9.8 19.4 -49.6%
3.8% 6.5% -2.7 PP
-0.9 10.3 –
-0.3% 3.5% -3.8 PP
18.5 23.8 -22.1%
3,232 3,595 -10.1%
Q1-3 2016
Q1-3 2015
restated2)
%
647.6 692.1 -6.4%
72.2 75.4 -4.2%
11.1% 10.9% +0.2PP
46.7 53.9 -13.5%
7.2% 7.8% -0.6 PP
23.4 40.1 -41.6%
1.14 1.95 -41.6%
44.3 51.5 -14.0%
7,028 7,303 -3.8%
Semperit Group1)
1) Including Corporate Center (Holding, central functions, special projects): Costs of EUR 9.6m in Q1-3 2016 (EUR 20.1m in Q1-3 2015)
2) Values for 2015 restated 3) Attributable to shareholders of Semperit AG Holding

Semperit Group per quarter
in EUR m FY 2014 Q1 2015 Q2 2015 Q3 2015 Q4 2015 FY 2015 Q1 2016 Q2 2016 Q3 2016
Revenue 858.3 217.5 233.4 241.3 222.6 914.7 219.5 219.2 208.9
EBITDA 101.9 21.8 28.5 25.1 20.8 96.2 26.7 26.1 19.4
EBITDA margin 11.9% 10.0% 12.2% 10.4% 9.4% 10.5% 12.2% 11.9% 9.3%
EBIT 63.8 15.2 21.0 17.7 12.8 66.7 18.6 17.6 10.4
EBIT margin 7.4% 7.0% 9.0% 7.3% 5.8% 7.3% 8.5% 8.0% 5.0%
Financial result -11.5 1.0 -5.2 -0.8 -3.0 -8.0 -5.9 -4.1 -2.7
Earnings after
tax
37.8 12.6 12.7 14.7 6.3 46.4 10.1 7.7 5.5
Earnings per
share in EUR2) 1.85 0.61 0.62 0.72 0.31 2.26 0.49 0.38 0.27
Key Financials Semperit Group1)
1) Values for 2014 and 2015 restated
2) Attributable to shareholders of Semperit AG Holding

Semperflex and Sempertrans per quarter
Revenue 202.1 55.4 52.5 48.3 47.1 203.4 52.8 53.6 47.2
EBITDA 48.5 13.6 13.3 11.0 8.3 46.1 13.3 13.9 9.8
EBITDA
margin
24.0% 24.6% 25.3% 22.7% 17.6% 22.7% 25.2% 26.0% 20.7%
EBIT 36.8 11.6 11.3 9.0 6.3 38.2 11.1 11.8 7.6
EBIT margin 18.2% 21.0% 21.5% 18.6% 13.4% 18.8% 21.1% 22.0% 16.1%
Key Financials Semperflex1)
Key Financials Sempertrans1)
Revenue 146.4 38.9 39.0 43.9 43.1 164.9 42.6 38.9 32.7
EBITDA 20.9 4.7 5.7 6.2 6.5 23.2 5.8 5.7 3.0
EBITDA
margin
14.3% 12.2% 14.6% 14.1% 15.1% 14.0% 13.6% 14.5% 9.2%
EBIT 16.8 4.0 4.9 5.4 5.7 19.9 4.8 4.7 2.1
EBIT margin 11.5% 10.2% 12.5% 12.2% 13.2% 12.1% 11.3% 12.1% 6.3%

Semperform and Sempermed per quarter
Key Financials Semperform1)
Key Financials Sempermed1)
Revenue 129.0 31.8 41.7 44.0 35.3 152.8 38.2 42.8 40.5
EBITDA 18.6 3.7 10.1 7.3 3.2 24.3 6.0 7.7 6.7
EBITDA
margin
14.5% 11.6% 24.2% 16.7% 9.0% 15.9% 15.6% 17.9% 16.4%
EBIT 12.7 2.8 8.8 5.9 1.5 19.1 4.3 5.9 4.8
EBIT
margin
9.9% 8.9% 21.2% 13.4% 4.4% 12.5% 11.2% 13.8% 11.9%
Revenue 380.8 91.4 100.1 105.1 97.0 393.7 85.9 83.8 88.6
EBITDA 33.5 4.8 6.8 7.8 10.0 29.4 6.1 1.8 1.9
EBITDA
margin
8.8% 5.2% 6.8% 7.5% 10.3% 7.5% 7.0% 2.2% 2.1%
EBIT 17.6 1.9 3.6 4.9 6.9 17.2 2.9 -1.7 -2.1
EBIT
margin
4.6% 2.1% 3.5% 4.6% 7.1% 4.4% 3.3% -2.0% -2.3%

Solid balance sheet structure and financial flexibility
Balance sheet structure 30 September 2016
Balance sheet total: EUR 969 m
Equity
Fixed
assets
Inventories
Trade
receivables
Cash and cash
equivalents
Liabilities from
redeemable non-
controlling interests
Provisions incl.
social capital
Other liabilities
incl. deferred taxes
Current assets
Corporate
Schuldschein loan
Liabilities to banks
 Cash and cash equivalents of EUR 131m despite
investment programme and optimisation of capital
structure
 Financial liabilities:
 Corporate Schuldschein loan of EUR 133m
 Net debt of EUR 216m
 Net debt / EBITDA of 2.32x
 Equity ratio of 37%
Financial profile as of 30 September 2016
555
361
131
133
133
48
70
126
214
143
Equity & LiabilitiesAssets
23

Key figures consolidated income statement
Key figures income statement (1/2)
in EUR m 2008 2009 2010
2011
restated1)
2012 2013
2014
restated2)
2015
restated2)
Q1-3
2016
Revenue 655.3 588.1 689.4 820.0 828.6 906.3 858.3 914.7 647.6
Changes inventories 5.0 -9.8 13.6 2.8 -1.9 9.4 -15.3 6.8 1.4
Own work capitalised 1.4 0.9 0.8 0.8 1.6 1.0 3.3 6.2 3.1
Other operating
income
25.1 22.5 38.0 33.8 32.8 24.4 18.5 9.1 6.2
Material costs -381.9 -297.0 -410.2 -513.1 -501.0 -510.7 -487.7 -555.8 -377.8
Personnel expenses -109.3 -99.7 -109.9 -117.9 -127.4 -152.8 -151.0 -164.8 -128.3
Other operating
expenses
-107.7 -102.2 -109.5 -116.6 -124.2 -145.8 -132.3 -137.1 -85,0
Share of profits from
joint ventures and
associated
companies
0.1 0.1 0.2 0.2 0.3 0.6 8.1 17.1 5.0
EBITDA 87.9 102.8 112.3 110.0 108.7 132.5 101.9 96.2 72.2
Depreciation -29.2 -33.2 -29.9 -29.7 -36.2 -44.7 -38.1 -29.5 -25.6
EBIT 58.7 69.6 82.3 80.4 72.5 87.8 63.8 66.7 46.7
30
1) Values for 2011 restated (see Annual Report 2012, Notes 2.18), values for 2010 not restated.

Key figures consolidated income statement
Key figures income statement (2/2)
in EUR m 2010
2011
restated1)
2012 2013
2014
restated3)
2015
restated3)
Q1-3 2016
EBIT 82.3 80.4 72.5 87.8 63.8 66.7 46.7
Financial income 1.9 1.7 2.2 1.9 1.4 29.2 12.2
Financial expenses -0.3 -0.5 -1.2 -4.0 -5.0 -31.8 -20.2
Profit/loss attributable to
redeemable non-
controlling interests
-21.0 -14.7 -15.0 -14.8 -7.8 -5.4 -4.7
Financial result -19.2 -13.4 -14.0 -16.9 -11.5 -8.0 -12.7
Earnings before tax 63.1 66.9 58.5 70.9 52.3 58.8 33.9
Income taxes -17.7 -15.2 -12.2 -16.0 -14.5 -12.4 -10.5
Earnings after tax 45.4 51.8 46.2 54.9 37.8 46.4 23.4
Earnings per share in
EUR2) 2.21 2.52 2.25 2.65 1.85 2.26 1.14
31

Balance sheet structure: Assets
in EUR thousand 30/09/2016 31/12/2015
ASSETS
Non-current assets
Intangible assets 111,869 111,314
Tangible assets 301,059 276,630
Investments in joint ventures and associated
companies
109,270 102,670
Other financial assets 11,701 12,372
Other assets 7,367 5,275
Deferred taxes 14,066 16,717
555,331 524,978
Current assets
Inventories 133,303 135,711
Trade receivables 125,962 125,519
Other financial assets 5,518 2,284
Other assets 11,417 16,670
Current tax receivables 6,441 6,192
Cash and cash equivalents 131,456 126,430
414,097 412,806
TOTAL ASSETS 969,428 937,784

Balance sheet structure: Equity and liabilities
EQUITY AND LIABILITIES 30/09/2016 31/12/2015
Equity
Share capital 21,359 21,359
Capital reserves 21,503 21,503
Revenue reserves 312,332 317,733
Currency translation reserve 3,803 2,664
Equity attributable to shareholders of Semperit AG Holding 358,997 363,260
Non-controlling interests 1,892 1,924
360,890 365,183
Non-current provisions and liabilities
Provisions for pension and severance payments 44,006 40,775
Other provisions 9,840 11,421
Liabilities from redeemable non-controlling interests 48,274 44,192
Corporate Schuldschein loan 132,659 132,615
Liabilities to banks 208,259 162,898
Other financial liabilities 770 862
Other liabilities 1,001 746
Deferred taxes 9,556 11,924
454,365 405,433
Current provisions and liabilities
Provisions for pension and severance payments 3,091 2,866
Other provisions 13,094 19,033
Corporate Schuldschein loan 617 1,481
Liabilities to banks 6,046 5,560
Trade payables 93,976 100,660
Other financial liabilities 19,688 13,762
Other liabilities 14,408 19,037
Current tax liabilities 3,253 4,769
154,173 167,168
EQUITY AND LIABILITIES 969,428 937,784
in EUR thousand

Key figures 2008 – 2015
Key performance figures
in EUR m 2008 2009 20101)
20111)
2012 2013 20143)
20153)
Revenue 655.3 588.1 689.4 820.0 828.6 906.3 858.3 914.7
EBITDA 87.9 102.8 112.3 110.0 108.7 132.5 101.9 96.2
EBITDA margin 13.4% 17.5% 16.3% 13.4% 13.1% 14.6% 11.9% 10.5%
EBIT 58.7 69.6 82.3 80.4 72.5 87.8 63.8 66.7
EBIT margin 9.0% 11.8% 11.9% 9.8% 8.8% 9.7% 7.4% 7.3%
Earnings after tax 44.9 38.8 45.4 51.8 46.2 54.9 37.8 46.4
Earnings per share (EPS)2)
, in EUR 1.83 1.89 2.21 2.52 2.25 2.65 1.85 2.26
Gross cash flow 78.0 92.6 91.0 89.4 85.6 116.2 89.9 55.7
Return on equity 12.9% 12.5% 12.9% 13.6% 11.4% 13.3% 8.6% 12.8%
Balance sheet key figures
in EUR m 2008 2009 20101)
20111)
2012 2013 20143)
2015
Balance sheet total 485.5 531.5 593.5 616.7 824.5 852.1 826.3 937.8
Equity2)
291.9 310.6 351.1 379.4 406.2 411.5 443.8 363.3
Equity ratio 60.1% 58.4% 59.2% 61.5% 49.3% 48.3% 53.7% 38.7%
Investments in tangible and intangible assets 27.6 22.7 52.5 45.1 41.2 49.7 67.4 71.8
Employees (at balance sheet date) 7,064 6,649 7,019 8,025 9,577 10,276 6,888 7,053

> 54%
> 5%
< 41%
B & C Holding Österreich GmbH, Vienna, Austria
FMR Co., Inc (Fidelity
Management & Research Company)
Free Float
 Semperit is listed on the Vienna
Stock Exchange since 1890
 Total of 20,573,434 shares with
a market capitalization of more than
EUR 500m (mid November 2016)
 B & C Holding Österreich GmbH is part
of B & C Privatstiftung, an Austrian
based private foundation / trust
 Primary focus of B & C is pursuing the
foundation’s mission to “foster Austrian
entrepreneurship”
 Semperit benefits from a supportive
ownership structure with long-term
commitment from B & C
 Fidelity Management and Research is
an American multinational financial
services corporation
Shareholder structure
Shareholder Structure

2016 11-17 investor presentation november-2016

Recommended

Recommended

More Related Content

What's hot

What's hot (18)

Viewers also liked

Viewers also liked (13)

Similar to 2016 11-17 investor presentation november-2016

Similar to 2016 11-17 investor presentation november-2016 (20)

Recently uploaded

Recently uploaded (14)

2016 11-17 investor presentation november-2016

Editor's Notes